Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...

(Yicai) Jan. 3 -- US pharmaceutical company Gilead Sciences has been given the greenlight by Chinese regulators to sell its ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The ...

Gilead abandoned testing of the antibody in ... the drug is still in clinical development in China. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...